BLRX : Summary for BioLineRx Ltd. - American Depos - Yahoo Finance

U.S. Markets open in 24 mins.

BioLineRx, Ltd. (BLRX)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.01+0.01 (+1.00%)
At close: 4:00 PM EST
People also watch:
CANFCPRXAVEOBIOCCNAT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close1.00
Open0.00
Bid0.95 x 100
Ask1.40 x 2000
Day's Range0.99 - 1.02
52 Week Range0.71 - 1.42
Volume131,854
Avg. Volume359,595
Market Cap58.41M
Beta-0.17
PE Ratio (TTM)-3.70
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

    BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase 2a correlative data, as well as detailed mechanism-of-action data, for BL-8040, the Company's leading oncology platform at the ongoing 58th American Society of Hematology (ASH) Annual Meeting and Exhibition in San Diego, California. As previously announced, in an oral presentation at 10:30am PST today, entitled, "The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and their Terminal Differentiation by Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of miR-15a/16-1 Expression," BioLineRx reports detailed data on the mechanism-of-action by which BL-8040 directly induces apoptosis of AML cells.

  • PR Newswire17 days ago

    BioLineRx Reports Third Quarter 2016 Financial Results

    TEL AVIV, Israel, Nov. 22, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...

  • PR Newswire18 days ago

    BioLineRx In-licenses Novel Anti-Inflammatory Treatment for Dry Eye Syndrome Under Strategic Collaboration with Major Global Pharmaceutical Company

    BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has signed an exclusive, worldwide agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., for the in-licensing of a novel anti-inflammatory treatment for Dry Eye Syndrome (DES). This project, to be named BL-1230, is the third project in-licensed under the framework of the Company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.